This content is first seen at HSA
Disclaimer: The information provided in this site is correct at the time of publication. POMConnect assumes no responsibility or liability for any errors or omissions in the content of this site.
| Product Name | REXULTI FILM COATED TABLETS 0.25MG, 0.5MG, 1MG, 2MG, 3MG, 4MG |
| Active Ingredient | Brexpiprazole |
| Product Registrant | LUNDBECK SINGAPORE PTE LTD |
| Date of Approval | 02/05/2023 |
| Indications: Treatment of schizophrenia (see section 5.1) in adults and pediatric patients aged 13 years and older. | |
| Product Name | RINVOQ EXTENDED-RELEASE TABLET 15MG, 30MG, 45MG |
| Active Ingredient | Upadacitinib Hemihydrate eqv Upadacitinib |
| Product Registrant | ABBVIE PTE. LTD. |
| Date of Approval | 11/05/2023 |
| Indications: RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. | |
| Product Name | KEYTRUDA SOLUTION FOR INFUSION 25 MG/ML |
| Active Ingredient | Pembrolizumab |
| Product Registrant | MSD PHARMA (SINGAPORE) PTE. LTD. |
| Date of Approval | 17/05/2023 |
| Indications: Melanoma KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC or III melanoma who have undergone complete resection. Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with an anti-angiogenic tyrosine kinase inhibitor (TKI). Renal Cell Carcinoma KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of patients with advanced RCC. Endometrial Carcinoma KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. | |
| Product Name | FORXIGA TABLET 5MG, 10MG |
| Active Ingredient | Dapagliflozin propanediol |
| Product Registrant | ASTRAZENECA SINGAPORE PTE LTD |
| Date of Approval | 26/05/2023 |
| Indications:FORXIGA is indicated in adults with heart failure (NYHA class II-IV) to reduce the risk of cardiovascular death and hospitalization for heart failure (see section 5.1). | |
Link to the original news (HSA) :
